Acetazolamide
As of the edition of 20 October 2026, Acetazolamide is a small molecule: marketed, first approved in 1955 (CH); acts on CA1, CA12 and CA2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- Diamox
- First approved
- 24 August 1955 (CH)
- Approvals on record
- 8 in 5 regions
- Holder of the most recent approval
- União Química Farmacêutica Nacional S/A; 6 holders in all
- Registered trials
- 88, 16 stopped early
- Disease areas
- Lungs and airways; Nervous system; Heart and blood vessels; Nutrition and metabolism; Eye; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Acetazolamide.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 8 | 3 | 3 |
| Phase 1 | 9 | 4 | 2 | 2 |
| Phase 2 | 25 | 10 | 7 | 6 |
| Phase 3 | 12 | 3 | 2 | 4 |
| Phase 4 | 23 | 14 | 6 | 1 |
| All trials | 88 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| União Química Farmacêutica Nacional S/A | Applicant | 2005 to now |
| Teva | Acquired holder | 2012 to now |
| Pfizer | Later holder |